When “the Greater Good” Matters The business pages, and now the mainstream media, have been dominated over the last week with news of Pfizer’s proposed $106bn takeover of AstraZeneca, which would make ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

Pfizer chief executive Ian Read is to go head-to-head with AstraZeneca's Pascal Soriot in two parliamentary hearings to argue for the future of the UK-based company. The two CEOs have been called ...

AstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan ...

Pfizer has confirmed that it made an offer of £46.61 ($76.62) per AstraZeneca share in January – a premium of around 30% to AstraZeneca's closing share on 3 January 2014, and valuing the firm ...

The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC ...

An AstraZeneca immunotherapy improved survival rates in patients with bladder cancer, results that could reshape treatment of ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

This summary covers various health news: a Nipah virus death in Kerala, Gaza's polio vaccination coverage success, brain ...

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

The business pages, and now the mainstream media, have been dominated over the last week with news of Pfizer's proposed $106bn takeover of AstraZeneca, which would make it the largest ever foreign ...